| Lauren O'toole, | |
|
5969 N Canton Center Rd, Canton, MI 48187-2757 | |
| (877) 407-3422 | |
| (877) 407-4329 |
| Full Name | Lauren O'toole |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 5969 N Canton Center Rd, Canton, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043936495 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 7101007725 (Michigan) | Primary |
| Provider Name | Fox Rehabilitation Services Mi Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1790324648 PECOS PAC ID: 2769819960 Enrollment ID: O20200228000658 |
News Archive
Using frozen stool from healthy, unrelated donors was safe and effective in treating patients with serious, relapsing diarrhea caused by Clostridium difficile, according to a new pilot study published in Clinical Infectious Diseases and available online.
As mRNA-based SARS-CoV-2 vaccines are deployed to protect hundreds of millions of people across the world and point the way to end the deadly global COVID-19 pandemic, the University of Pennsylvania scientists whose prescient discovery science effort laid the foundation for swift vaccine development have been awarded the 2021 Lasker~DeBakey Clinical Medical Research Award.
Genzyme Corporation today announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule.
IntelGenx Corp. is pleased to announce the results of a clinical pilot study that suggests IntelGenx has successfully developed a product that is bioequivalent to a leading branded anti-migraine therapy. The product (INT008) has been developed using IntelGenx's proprietary immediate release film "VersaFilm" drug delivery technology. VersaFilm provides a patent-protected method of formulating in a convenient and discrete dosage form.
In the current study, the researchers focused on the formation of the MIF protein (macrophage migration inhibitory factor), a proinflammatory protein that they showed in previous studies is elevated in diabetic animals and may be involved in the cascade of immunological events that leads to the destruction of the pancreas and the subsequent onset of type 1 diabetes.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lauren O'toole, 7 Carnegie Plz, Cherry Hill, NJ 08003-1000 Ph: (877) 407-3422 | Lauren O'toole, 5969 N Canton Center Rd, Canton, MI 48187-2757 Ph: (877) 407-3422 |
News Archive
Using frozen stool from healthy, unrelated donors was safe and effective in treating patients with serious, relapsing diarrhea caused by Clostridium difficile, according to a new pilot study published in Clinical Infectious Diseases and available online.
As mRNA-based SARS-CoV-2 vaccines are deployed to protect hundreds of millions of people across the world and point the way to end the deadly global COVID-19 pandemic, the University of Pennsylvania scientists whose prescient discovery science effort laid the foundation for swift vaccine development have been awarded the 2021 Lasker~DeBakey Clinical Medical Research Award.
Genzyme Corporation today announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule.
IntelGenx Corp. is pleased to announce the results of a clinical pilot study that suggests IntelGenx has successfully developed a product that is bioequivalent to a leading branded anti-migraine therapy. The product (INT008) has been developed using IntelGenx's proprietary immediate release film "VersaFilm" drug delivery technology. VersaFilm provides a patent-protected method of formulating in a convenient and discrete dosage form.
In the current study, the researchers focused on the formation of the MIF protein (macrophage migration inhibitory factor), a proinflammatory protein that they showed in previous studies is elevated in diabetic animals and may be involved in the cascade of immunological events that leads to the destruction of the pancreas and the subsequent onset of type 1 diabetes.
› Verified 5 days ago
North 42 Degrees Therapy Pllc Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 42842 Lombardy Dr, Canton, MI 48187 Phone: 734-361-9804 Fax: 734-353-4300 | |
Meredith Friend, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 44560 Ford Rd, Canton, MI 48187 Phone: 734-680-8780 | |
Callie Waldrep, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 44560 Ford Rd, Canton, MI 48187 Phone: 734-680-8780 | |
Patricia Dimaria, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 45707 Morningside Dr, Canton, MI 48187 Phone: 734-391-9668 | |
Megan Kasper, MA/CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6879 Kings Mill Dr, Canton, MI 48187 Phone: 419-215-1324 | |
Nicole Quirk, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 45570 Maben Rd, Canton, MI 48187 Phone: 313-999-1667 |